Status:
COMPLETED
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma
Lead Sponsor:
Swedish Medical Center
Collaborating Sponsors:
Bayer
Amgen
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Open label study of sorafenib
Detailed Description
Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than \< 100 cigarettes lifetime).
Eligibility Criteria
Inclusion
- Age \> 18
- Life expectancy \> 12 weeks
- Biopsy-proven BAC or adenocarcinoma
- Willing to provide smoking status
- Selected IIIB or stage IV cancer that is incompletely resected or unresectable
Exclusion
- O2 saturation \< 88% on room air
- Pregnant or nursing women
- Surgery or radiation therapy within 4 weeks of starting study
- Major heart condition within 6 months of starting therapy
- Certain concomitant medications prohibited
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00456716
Start Date
March 1 2007
End Date
December 1 2008
Last Update
March 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Cancer Institute
Seattle, Washington, United States, 98104